Androgenetic Alopecia as an Early Marker of Benign Prostatic Hyperplasia

    November 2012 in “ The Journal of Urology ”
    Steven A. Kaplan
    Image of study
    TLDR Early hair loss may indicate future prostate issues.
    A study conducted in 2012 found a relationship between androgenetic alopecia (AGA) and prostate growth-associated urinary symptoms, which may be attributable to their pathophysiological similarity. The study suggests that early-onset AGA may be an early marker of urinary/prostatic symptomatology. The study was an observational case-control study of 87 men: 45 with early-onset AGA diagnosed in the dermatology department and 42 control subjects. The groups did not significantly differ in mean age. Patients with AGA had significantly higher mean prostate volume, International Prostate Symptom Score, and prostate-specific antigen value and significantly lower maximum urinary flow versus control subjects. Binary logistic regression analysis showed a strong association between the presence of AGA and benign prostatic hyperplasia after adjusting for age, urinary volume, urination time, International Prostate Symptom Score, abdominal obesity, glucose levels, systolic blood pressure, insulin levels, fibrinogen, and C-reactive protein.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 1000+ results

      community Dermatologist told me to quit fin after turning 40

      in Finasteride/Dutasteride  194 upvotes 1 year ago
      A dermatologist advised a patient to stop taking finasteride (fin) after turning 40 due to potential risk of aggressive prostate cancer. The patient and others in the conversation debated this advice, discussing the relationship between finasteride, prostate cancer, and hair loss, and considering alternatives like topical finasteride.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 3 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

    Similar Research

    6 / 1000+ results